BD Exits Glucose Monitoring Market After Being “Eclipsed” By Competitors

Becton Dickinson is dropping out of the increasingly competitive blood glucose monitoring market, acknowledging that it has been too slow to innovate in a sector that generated about $105 mil. in BD sales for the 12 months ended Sept. 30

More from Archive

More from Medtech Insight